Green Cross Holds Symposium to Share Latest Insights on Hemophilia Treatment

GC Green Cross announced on the 26th that it successfully held a symposium on the 22nd at the Le Meridien Hotel in Myeongdong, Jung-gu, Seoul, to share the latest insights on hemophilia treatment with specialized medical professionals.

At the latest hemophilia symposium held on the 22nd, Professor Youngbae Choi of Ajou University School of Medicine, Professor Jungwoo Han of Yonsei University College of Medicine, Director Kiyoung Yoo of the Korea Hemophilia Foundation-affiliated clinic, Professor Jeonga Park of Inha University School of Medicine, Professor Youngsil Park of Kyung Hee University School of Medicine, and Professor Eunjin Choi of Daegu Catholic University are conducting a panel discussion.
[Photo by GC Green Cross]

At this symposium, Professor Eun-jin Choi of Daegu Catholic University’s Department of Pediatrics chaired the session, and Professor Jung-ah Park of Inha University Hospital’s Department of Pediatrics presented on the topic "Evolution of the Hemophilia Treatment Environment," discussing the advantages, disadvantages, and characteristics of the latest treatments including conventional Factor Replacement Therapy and Nonfactor Therapy.

Professor Park stated, “It is essential to select treatments that fully consider the patient’s key variables and condition,” adding, “As various new drugs are being released in the field of hemophilia treatment recently, it is important to clearly understand the characteristics of both new and existing treatments and establish the optimal treatment strategy tailored to each patient.” She also noted, “When looking at physical activity according to coagulation factor levels in the body, conventional Factor Replacement Therapy remains effective.”

Professor Choi said, “While welcoming the release of various new hemophilia treatments including Nonfactor Therapy and gene therapy, it is true that there are concerns about long-term safety,” and emphasized, “A comprehensive treatment strategy considering the patient’s risk factors must be implemented.”

After the presentation session, during the panel discussion, domestic hemophilia specialists including Professor Young-sil Park of Kangdong Kyung Hee University Hospital gathered to share opinions on the latest treatment insights regarding coagulation factor and nonfactor therapies. The experts stressed, “As many new drugs are about to be released, it is a time when guidelines for the safe use of these new drugs are necessary.”

Nam-gung Hyun, Head of Domestic Sales Division at GC Green Cross, said, “This symposium was organized to think together with doctors who work day and night to ensure that hemophilia patients receive optimized treatment in clinical settings, as well as to consider directions for the best treatment options tailored to individual patients,” adding, “We will continue to fulfill our responsibility and mission to help medical professionals build a better treatment environment for patients.”

This content was produced with the assistance of AI translation services.